AMNON PELED has a total of 13 patent applications. It increased the IP activity by 200.0%. Its first patent ever was published in 2009. It filed its patents most often in Israel. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are NYCOMED DAK AS, BIOHAVEN PHARM HOLDING CO LTD and TESARO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Israel | 13 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Peptides | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Amnon Peled | 12 |
#2 | Michal Abraham | 8 |
#3 | Katia Beider | 4 |
#4 | Michal Begin | 4 |
#5 | Yaron Pereg | 4 |
#6 | Orly Eizenberg | 4 |
Publication | Filing date | Title |
---|---|---|
IL244329D0 | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery | |
IL229151D0 | A t-140 peptide analog having cxcr4 super-agonist activity and an anti-cd20 for lymphoma therapy | |
IL218405D0 | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery | |
IL216978D0 | Chemokine binding polypeptides capable of inihibiting the course of autoimmunity, inflammation and cancer | |
IL210247D0 | Ccl20 - specific antibodies for cancer therapy |